BJU Int
- VAN DEN EYNDE L, Ost P, Verla W, Everaerts W, et al 
 Feasibility of randomisation to radical prostatectomy or standard care in 
patients with metastatic prostate cancer.
 BJU Int. 2025 Sep 20. doi: 10.1111/bju.70006.
 
 
 Br J Cancer
 
 
- CHANG YH, Bresnahan ST, Taylor Head S, Harrison TA, et al 
 Isoform-level analyses of 6 cancers uncover extensive genetic risk mechanisms 
undetected at the gene-level.
 Br J Cancer. 2025;133:874-885.
 
 
 Br J Radiol
 
 
- LANDRY C, Klusa D, Cochonneau D, Supiot S, et al 
 Circulating tumor cells for the prediction of the response to radiation therapy 
in prostate cancer.
 Br J Radiol. 2025 Sep 13:tqaf224. doi: 10.1093.
 
 
 Clin Imaging
 
 
- DEFFLER C, Sedeh AE, Leitman E, Ng TSC, et al 
 The role of PSMA PET/CT in identifying benign and malignant intracranial lesions 
in patients with prostate cancer.
 Clin Imaging. 2025 Sep 12:110620. doi: 10.1016/j.clinimag.2025.110620.
 
 
 Eur Urol
 
 
- ENGLMAN C, Adebusoye B, Mallett S, Giganti F, et al 
 Reply to Yuan Du, Dan Liu, and Zhihui Guan's Letter to the Editor re: Cameron 
Englman, Busola Adebusoye, Davide Maffei, et al. Magnetic Resonance Imaging-led 
Risk-adapted Active Surveillance for Prostate Cancer: Updated Results from a 
Large Cohort Stu
 Eur Urol. 2025 Sep 18:S0302-2838(25)00500-7. doi: 10.1016/j.eururo.2025.
 
 
 Int J Urol
 
 
- MIYOSHI Y, Uemura H, Ohta J, Kobayashi K, et al 
 Prognostic Value of BONENAVI Computer-Aided Diagnosis System Bone Scans as an 
Imaging Biomarker for Bone-Metastatic Castration-Sensitive Prostate Cancer: An 
Investigator-Initiated, Multicenter, Prospective Observational Study.
 Int J Urol. 2025 Sep 23. doi: 10.1111/iju.70214.
 
 
 J Natl Cancer Inst
 
 
- VERTOSICK EA, Vickers A, Dahlin A, Ulmert D, et al 
 Prostate-specific antigen levels at age 60 and lifetime risk of lethal prostate 
cancer.
 J Natl Cancer Inst. 2025 Sep 19:djaf271. doi: 10.1093.
 
 
 Lancet Oncol
 
 
- GRUBER K 
 Prostate cancer screening bill before NZ Parliament.
 Lancet Oncol. 2025 Sep 18:S1470-2045(25)00557.
 
 
 Oncogene
 
 
- SHENG H, Shi G, Lu Y, Zheng S, et al 
 KBTBD11 loss promotes AKT hyperactivation and therapeutic vulnerability in 
prostate cancer.
 Oncogene. 2025 Sep 23. doi: 10.1038/s41388-025-03576.
 
 
- GE Y, Han P, Sun Y, Chen Y, et al 
 Aging-associated ZNF573 methylation regulates RNF19B-PIK3CA ubiquitination to 
promote prostate cancer.
 Oncogene. 2025 Sep 19. doi: 10.1038/s41388-025-03579.
 
 
- CHUKHU M, Dahiya UR, Heemers HV 
 Evolving roles for the androgen receptor and its protein interactome in 
castration-resistant prostate cancer.
 Oncogene. 2025 Sep 18. doi: 10.1038/s41388-025-03573.
 
 
 Oncol Rep
 
 
- NAKAYAMA M, Takagi-Maeda S, Machino Y, Nihira K, et al 
 Novel tetravalent bispecific antibody, PSMA/TRAIL?R2 REGULGENT, induces 
selective tumor cell apoptosis without hepatotoxicity.
 Oncol Rep. 2025;54:155.
 
 
 PLoS One
 
 
- HWANG J, Kang BH, Park Y, Choi DH, et al 
 Improving segmentation precision in prostate cancer adaptive radiation therapy 
with a patient-specific network.
 PLoS One. 2025;20:e0332603.
 
 
- DAMKLIANG K, Thongsuksai P, Wongsirichot T, Kayasut K, et al 
 Detection and score grading for prostate adenocarcinoma using semantic 
segmentation.
 PLoS One. 2025;20:e0331613.
 
 
 Proc Natl Acad Sci U S A
 
 
- CHOWDHURY SR, Parikh CN, Kaur AN, DeMarco KD, et al 
 PPT1 is a negative regulator of STING signaling in cancer cells and its 
inhibition reactivates immune surveillance in cold tumors.
 Proc Natl Acad Sci U S A. 2025;122:e2514948122.
 
 
 Prostate
 
 
- HOGGARD NK, Berg FM, Szczepaniak MR, Wang X, et al 
 Pathology of a Canine Model of Localized Prostate Carcinoma.
 Prostate. 2025 Sep 22. doi: 10.1002/pros.70054.
 
 
- YANEZ-CASTILLO YM, Melgarejo-Segura MT, Arrabal-Polo MA, Jimenez-Pacheco A, et al 
 Enhancing Prostate Cancer Diagnosis: The Combined Value of PHI and mpMRI.
 Prostate. 2025 Sep 22. doi: 10.1002/pros.70055.
 
 
- LI C, He C, Pan J, Feng Y, et al 
 MIF Facilitates Resistance to Androgen Deprivation Therapy by Regulating AMPD2 
Expression in Prostate Cancer Cells.
 Prostate. 2025 Sep 19. doi: 10.1002/pros.70053.
 
 
- PEINADO BRR, Nazario RMF, Frazao DR, Ne YGS, et al 
 Is There Any Association Between Periodontitis and Prostatic Alterations? A 
Systematic Review.
 Prostate. 2025;85:1369-1385.
 
 
- SANDOVAL V, Osinski T, Malshy K, Feng C, et al 
 Long-Term Oncological Outcomes of Robot-Assisted Radical Prostatectomy for 
Clinically Localized Grade Groups 4 and 5 Prostate Cancers Diagnosed on Prostate 
Biopsy.
 Prostate. 2025;85:1432-1439.
 
 
- BORQUE-FERNANDO A, Guerrero-Ochoa P, Esteban LM, Hernandez A, et al 
 Integration of Primary Care Into the Follow-Up Protocol for Prostate Cancer 
Patients in Aragon, Spain. It Is Time to Follow Other Successful Models in the 
Region.
 Prostate. 2025 Sep 24. doi: 10.1002/pros.70057.
 
 
 Radiol Imaging Cancer
 
 
- GARG T, Wehrenberg-Klee E 
 New Frontier for Prostate Artery Embolization: Neoadjuvant PAE before Radiation 
Therapy in Patients with Prostate Cancer.
 Radiol Imaging Cancer. 2025;7:e259023.
 
 
- FIELDS BKK, Hassan OT 
 An MRI Histopathology-based Deep Learning Approach for the Classification of 
Prostate Cancer.
 Radiol Imaging Cancer. 2025;7:e250466.
 
 
- NGUYEN C, Hulsey G, James K, James T, et al 
 Deep Learning Classification of Prostate Cancer Using MRI Histopathologic Data.
 Radiol Imaging Cancer. 2025;7:e240381.
 
 
 
Free Medical Abstracts
 Privacy Policy
Privacy Policy
 Sponsors
Sponsors
 Share
Share
© Amedeo 1997-2016